MVIS US Listed Biotech 25 Index
The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that generate at least 50% of their revenues from biotechnology. The pure-play index contains only companies which are engaged primarily in research and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. The MVIS US Listed Biotech 25 Index (MVBBH) has been licensed to underlie financial products with currently USD 367.5 million in assets under management.
This page compares selected fundamental data of the MVIS Index to designated peer indices. The data is updated monthly.
|Trailing Price/Earnings (incl. negative)||67.08 |
|Price/Cash Flow||15.98 |
|Dividend Yield||0.68 |
|Net Debt to Equity||-2.19 |